- Home
- DGICA vs DAWN Comparison
DGICA vs DAWN Comparison
Compare DGICA & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- DAWN
- Stock Information
- Founded
- DGICA 1986
- DAWN 2018
- Country
- DGICA United States
- DAWN United States
- Employees
- DGICA N/A
- DAWN N/A
- Industry
- DGICA Property-Casualty Insurers
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- DAWN Health Care
- Exchange
- DGICA Nasdaq
- DAWN Nasdaq
- Market Cap
- DGICA 683.3M
- DAWN 658.9M
- IPO Year
- DGICA N/A
- DAWN 2021
- Fundamental
- Price
- DGICA $18.28
- DAWN $7.02
- Analyst Decision
- DGICA Hold
- DAWN Strong Buy
- Analyst Count
- DGICA 1
- DAWN 7
- Target Price
- DGICA $18.00
- DAWN $31.57
- AVG Volume (30 Days)
- DGICA 186.2K
- DAWN 1.3M
- Earning Date
- DGICA 07-24-2025
- DAWN 07-29-2025
- Dividend Yield
- DGICA 3.99%
- DAWN N/A
- EPS Growth
- DGICA 1206.68
- DAWN N/A
- EPS
- DGICA 2.03
- DAWN N/A
- Revenue
- DGICA $993,637,805.00
- DAWN $161,922,000.00
- Revenue This Year
- DGICA $3.27
- DAWN $17.98
- Revenue Next Year
- DGICA $4.01
- DAWN $49.50
- P/E Ratio
- DGICA $8.99
- DAWN N/A
- Revenue Growth
- DGICA 5.29
- DAWN N/A
- 52 Week Low
- DGICA $12.92
- DAWN $6.08
- 52 Week High
- DGICA $21.12
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- DGICA 35.80
- DAWN 58.34
- Support Level
- DGICA $18.68
- DAWN $6.52
- Resistance Level
- DGICA $19.40
- DAWN $7.24
- Average True Range (ATR)
- DGICA 0.51
- DAWN 0.26
- MACD
- DGICA -0.11
- DAWN 0.07
- Stochastic Oscillator
- DGICA 5.50
- DAWN 78.37
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.